Jamesi Novum (Metformin Hydrochloride, Sitagliptin)

Jamesi Novum combines metformin and sitagliptin to target hyperglycaemia in type 2 diabetes mellitus.

• Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
• Type 2 diabetes mellitus (combination therapy): adds glycaemic control when used with other oral antidiabetics or insulin.
• Adults with inadequate glycaemic control on metformin alone: provides additional glucose reduction through DPP‑4 inhibition.

• Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, decreasing glucose output and increasing glucose uptake. Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins stimulate glucose‑dependent insulin secretion and suppress glucagon release, together producing improved overall glycaemic control.

Jamesi Novum may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhoea: loose stools, often transient.
• Abdominal discomfort: cramping or pain.
• Headache: mild tension‑type headache.
• Upper respiratory tract infection: cold‑like symptoms.
• Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: acute inflammation of the pancreas.
• Stevens‑Johnson syndrome: severe skin reaction.
• Hepatic failure: rare liver dysfunction.
• Renal impairment worsening: decline in kidney function.

Before prescribing Jamesi Novum, clinicians should consider several safety precautions.

• Renal function assessment: evaluate eGFR and avoid use in severe renal impairment.
• Hepatic function monitoring: use with caution in patients with liver disease.
• Lactic acidosis risk: discontinue if signs of metabolic acidosis appear.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks.
• Concomitant hypoglycaemic agents: monitor for enhanced hypoglycaemia.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Jamesi Novum can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Iodinated contrast media: may precipitate acute renal failure, increasing metformin accumulation.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise metformin plasma levels.
• Potent DPP‑4 inhibitors (e.g., saxagliptin) combined with sitagliptin: increase risk of adverse effects.
• Insulin or sulfonylureas: may cause severe hypoglycaemia.
• Renal‑impairing drugs (e.g., high‑dose NSAIDs): exacerbate metformin accumulation.

Moderate Interactions (Monitor Closely)

• Diuretics: affect renal clearance of metformin.
• ACE inhibitors or ARBs: may influence renal function, requiring dose adjustment.
• Beta‑blockers: can mask hypoglycaemia symptoms.
• Corticosteroids: increase blood glucose, possibly reducing drug efficacy.
• Alcohol: can potentiate lactic acidosis risk.